Cargando…

Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies

Pancreatic ductal adenocarcinoma (PDAC), which constitutes 90% of pancreatic cancers, is the fourth leading cause of cancer-related deaths in the world. Due to the broad heterogeneity of genetic mutations and dense stromal environment, PDAC belongs to one of the most chemoresistant cancers. Most of...

Descripción completa

Detalles Bibliográficos
Autores principales: Adamska, Aleksandra, Domenichini, Alice, Falasca, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5535831/
https://www.ncbi.nlm.nih.gov/pubmed/28640192
http://dx.doi.org/10.3390/ijms18071338
_version_ 1783253904052453376
author Adamska, Aleksandra
Domenichini, Alice
Falasca, Marco
author_facet Adamska, Aleksandra
Domenichini, Alice
Falasca, Marco
author_sort Adamska, Aleksandra
collection PubMed
description Pancreatic ductal adenocarcinoma (PDAC), which constitutes 90% of pancreatic cancers, is the fourth leading cause of cancer-related deaths in the world. Due to the broad heterogeneity of genetic mutations and dense stromal environment, PDAC belongs to one of the most chemoresistant cancers. Most of the available treatments are palliative, with the objective of relieving disease-related symptoms and prolonging survival. Currently, available therapeutic options are surgery, radiation, chemotherapy, immunotherapy, and use of targeted drugs. However, thus far, therapies targeting cancer-associated molecular pathways have not given satisfactory results; this is due in part to the rapid upregulation of compensatory alternative pathways as well as dense desmoplastic reaction. In this review, we summarize currently available therapies and clinical trials, directed towards a plethora of pathways and components dysregulated during PDAC carcinogenesis. Emerging trends towards targeted therapies as the most promising approach will also be discussed.
format Online
Article
Text
id pubmed-5535831
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-55358312017-08-04 Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies Adamska, Aleksandra Domenichini, Alice Falasca, Marco Int J Mol Sci Review Pancreatic ductal adenocarcinoma (PDAC), which constitutes 90% of pancreatic cancers, is the fourth leading cause of cancer-related deaths in the world. Due to the broad heterogeneity of genetic mutations and dense stromal environment, PDAC belongs to one of the most chemoresistant cancers. Most of the available treatments are palliative, with the objective of relieving disease-related symptoms and prolonging survival. Currently, available therapeutic options are surgery, radiation, chemotherapy, immunotherapy, and use of targeted drugs. However, thus far, therapies targeting cancer-associated molecular pathways have not given satisfactory results; this is due in part to the rapid upregulation of compensatory alternative pathways as well as dense desmoplastic reaction. In this review, we summarize currently available therapies and clinical trials, directed towards a plethora of pathways and components dysregulated during PDAC carcinogenesis. Emerging trends towards targeted therapies as the most promising approach will also be discussed. MDPI 2017-06-22 /pmc/articles/PMC5535831/ /pubmed/28640192 http://dx.doi.org/10.3390/ijms18071338 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Adamska, Aleksandra
Domenichini, Alice
Falasca, Marco
Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies
title Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies
title_full Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies
title_fullStr Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies
title_full_unstemmed Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies
title_short Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies
title_sort pancreatic ductal adenocarcinoma: current and evolving therapies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5535831/
https://www.ncbi.nlm.nih.gov/pubmed/28640192
http://dx.doi.org/10.3390/ijms18071338
work_keys_str_mv AT adamskaaleksandra pancreaticductaladenocarcinomacurrentandevolvingtherapies
AT domenichinialice pancreaticductaladenocarcinomacurrentandevolvingtherapies
AT falascamarco pancreaticductaladenocarcinomacurrentandevolvingtherapies